

**THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document or what action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended). The whole of this Document should be read, but your attention is in particular drawn to the letter from the Chairman of this Document.**

If you have sold or otherwise transferred, or you sell or otherwise transfer, all of your holding of Ordinary Shares in Summit Therapeutics PLC please send this Document together with the accompanying Form of Proxy at once to the purchaser or transferee or to the stockbroker, bank or other agent through or by whom the sale or transfer was or is effected, for onward delivery to the purchaser or transferee.

Copies of this Document are available, free of charge, at the registered office of Summit Therapeutics PLC at 85b Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY from 16 June 2016 until 18 July 2016.

---

# Summit Therapeutics PLC

(Incorporated and registered in England and Wales under number 05197494)

## NOTICE OF ANNUAL GENERAL MEETING

---

No person should construe the contents of this Document as legal, tax or financial advice and recipients of this Document should consult their own advisers as to the matters described in this Document.

Notice of an Annual General Meeting of Summit Therapeutics PLC to be held at the Milton Park Innovation Centre, 99 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY at 10.30 a.m. on 18 July 2016 is set out at the end of this Document. Shareholders will find enclosed with this Document a Form of Proxy for use at the Annual General Meeting. To be valid, the Form of Proxy, completed in accordance with the instructions thereon, should be returned as soon as possible but, in any event, so as to be received by Capita Asset Services, PXS, 34 Beckenham Road, Beckenham, Kent BR3 4TU at least 48 hours before the time appointed for the meeting (excluding non-working days).

### Cautionary note regarding forward-looking statements

This Document contains statements about Summit Therapeutics PLC that are or may be "forward-looking statements". All statements, other than statements of historical facts, included in this Document may be forward-looking statements. Without limitation, any statements preceded or followed by, or that include, the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "should", "anticipates", "estimates", "projects" or words or terms of similar substance or the negative thereof, are forward-looking statements. Forward-looking statements include statements relating to the following: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects and (ii) business and management strategies and the expansion and growth of the operations of Summit Therapeutics PLC; and (iii) the availability and timing of data from on-going and future clinical and preclinical trials, and the results of such trials. These forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Summit Therapeutics PLC. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person, or industry results, to be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate in the future. Investors should not place undue reliance on such forward-looking statements and, save as is required by law or regulation (including to meet the requirements of the AIM Rules, the Disclosure and Transparency Rules and/or the Prospectus Rules), Summit Therapeutics PLC does not undertake any obligation to update publicly or revise any forward-looking statements (including to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based). All subsequent oral or written forward-looking statements attributed to Summit Therapeutics PLC or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements contained in this Document are based on information available to the Directors of Summit Therapeutics PLC at the date of this Document, unless some other time is specified in relation to them, and the Posting or receipt of this Document shall not give rise to any implication that there has been no change in the facts set forth herein since such date.

### Notice to overseas persons

The distribution of this Document in certain jurisdictions may be restricted by law and therefore persons into whose possession this Document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

# Table of Contents

Definitions	2
Expected Timetable of Principal Events	2
Letter from the Chairman of Summit Therapeutics PLC	3
Notice of Annual General Meeting	6

## Definitions

<b>"AIM"</b>	AIM, a market operated by the London Stock Exchange
<b>"Annual General Meeting" or "AGM"</b>	the Annual General Meeting of the Company to be held at the Milton Park Innovation Centre, 99 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY at 10.30 a.m. on 18 July 2016, notice of which is set out at the end of this Document
<b>"Articles"</b>	the articles of association of the Company as adopted by special resolution passed on 19 February 2015
<b>"Business Day"</b>	a day (other than a Saturday or Sunday) on which commercial banks are open for general business in London, England
<b>"Capita" or "Registrars"</b>	Capita Asset Services, a trading name for Capita Registrars Limited, being the Company's registrars
<b>"Company" or "Summit"</b>	Summit Therapeutics PLC (registered number 05197494)
<b>"CREST"</b>	the electronic settlement system for UK and Irish securities operated by Euroclear UK & Ireland Limited
<b>"Directors" or "Board"</b>	the directors of the Company
<b>"Document"</b>	this document
<b>"London Stock Exchange"</b>	London Stock Exchange PLC
<b>"Ordinary Shares"</b>	61,467,785 Ordinary Shares of one penny each in the capital of the Company
<b>"Posting"</b>	the posting of this Document and form of proxy
<b>"Registrar of Companies"</b>	means the Registrar of Companies under the Companies Act 2006
<b>"Resolutions"</b>	the resolutions set out in the AGM notice on page 6 of this Document
<b>"Shareholders"</b>	the holders of the Ordinary Shares in the Company as at the date of this Document
<b>"UK" or "United Kingdom"</b>	the United Kingdom of Great Britain and Northern Ireland
<b>"£" or "pounds"</b>	Great British pounds, the basic unit of currency in the United Kingdom

## Expected Timetable of Principal Events

Date of this Document and Posting of the Form of Proxy	16 June 2016
Latest time and date for receipt of the Form of Proxy	10.30 a.m. on 14 July 2016
Annual General Meeting	10.30 a.m. on 18 July 2016

### Notes:

- (1) References to times in this Document are to British Summer Time (unless otherwise stated).
- (2) The timing of the events in the above timetable and in the rest of this Document is indicative only and may be subject to change.
- (3) If any of the above times or dates should change, the revised times and/or dates will be notified by an announcement to a regulatory information service.

# Letter from the Chairman of Summit Therapeutics PLC

85b Park Drive  
Milton Park  
Abingdon  
Oxfordshire  
OX14 4RY UK

Registered Number: 05197494

16 June 2016

*To all holders of Ordinary Shares*

Dear Shareholder

## **1. Notice of 2015 Annual General Meeting**

Summit's annual report for the financial year ended 31 January 2016 ("2016 Annual Report") has now been published. A copy of the 2016 Annual Report is enclosed and an electronic version is also available from the Investors section of the Company's website, [www.summitplc.com](http://www.summitplc.com).

The 2016 Annual General Meeting is to be held at the Milton Park Innovation Centre, 99 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY at 10.30 a.m. on 18 July 2016. A summary and explanation of each of the Resolutions being proposed at the meeting is set out in section 2 on pages 3 and 4. Please note that this is not the full text of the Resolutions and you should read section 2 in conjunction with the Resolutions contained in the Notice of Annual General Meeting at the end of this Document.

**The purpose of this letter is to outline the details of the business to be conducted at the AGM, explain why the Directors unanimously consider these proposals to be in the best interests of the Company and Shareholders as a whole, and to seek Shareholders' approval for these resolutions.**

## **2. Annual General Meeting and Resolutions**

The business to be conducted at the AGM consists of consideration of the following resolutions:

### **Resolution 1: Receiving the Company's accounts**

An ordinary resolution to receive and adopt the report of the Directors and the accounts for the year ended 31 January 2016, together with the report of the auditors and the strategic report.

### **Resolution 2: Re-appointment of the Company's auditors**

An ordinary resolution to approve the re-appointment of PricewaterhouseCoopers LLP as the Company's auditor to hold office until the conclusion of the next general meeting at which accounts are laid before the Company at a remuneration to be fixed by the Directors of the Company from time to time.

### **Resolution 3: Approval of the Directors' Remuneration Policy (2016)**

An ordinary resolution to approve the Directors' Remuneration Policy (2016).

The Directors' Remuneration Policy (2016), which may be found on pages 30 to 37 of the 2016 Annual Report, gives details of the remuneration policy being proposed by the Remuneration Committee, for the Executive Directors, and the Non-Executive Directors.

Under regulations which now form part of the Companies Act 2006, the remuneration policy must be put to a binding shareholder vote at least once every three years. Shareholders will be invited to approve the Directors' Remuneration Policy (2016) by passing Resolution 3 at the AGM.

If so approved, the 2016 policy will take effect from the conclusion of the meeting. Once effective, all future payments to directors, past and present, must comply with the terms of the policy, unless specifically approved by shareholders in general meeting.

# Letter from the Chairman of Summit Therapeutics PLC continued

## **Resolution 4: Approving the Directors' Remuneration Report**

An ordinary resolution to approve the Directors' Remuneration Report.

The Directors' Remuneration Report, which may be found on pages 38 to 44 of the 2016 Annual Report, gives details of the Directors' remuneration for the year ended 31 January 2016.

The Company's auditors, PricewaterhouseCoopers LLP, have audited those parts of the Directors' Remuneration Report that are required to be audited and their report may be found on pages 46 to 47 of the 2016 Annual Report.

The Board considers that appropriate executive remuneration plays a vital part in helping to achieve the Company's overall objectives and, accordingly, in compliance with legislation, shareholders will be invited to approve the Directors Remuneration Report. This resolution is subject to an 'advisory vote' by shareholders: in the event that the resolution is not passed, the Directors' Remuneration Policy would normally need to be reconsidered by shareholders at the next AGM. The approval of the new Directors' Remuneration Policy (if passed in accordance with Resolution 3 above) would remain in force notwithstanding any failure to pass Resolution 4.

## **Resolution 5: Re-election of a Director**

An ordinary resolution to re-elect Professor Stephen Davies as a Director of the Company, who retires in accordance with the Articles and is eligible for re-election.

## **Resolution 6: Re-election of a Director**

An ordinary resolution to re-elect Mr Leopoldo Zambelletti as a Director of the Company, who retires in accordance with the Articles and is eligible for re-election.

## **Resolution 7: Re-election of a Director**

An ordinary resolution to re-elect Dr Barry Price as Director of the Company. Dr Price has served as a Director of the Company for nine years from the date of his first election and, in accordance with the UK Corporate Governance Code, retires and is proposed for re-election.

## **Resolution 8: Authority to allot Ordinary Shares**

An ordinary resolution, pursuant to section 551 of the Act, to generally and unconditionally authorise the Directors of the Company, in addition to any such authority previously granted and which has not expired, to issue and allot, or grant rights to subscribe for or convert any securities into, up to such number of Ordinary Shares of one penny each in the capital of the Company as is equal to one third of the number of Ordinary Shares in issue at 5.00 p.m. BST on 17 July 2016 (or, if such number is not a whole number, then the nearest whole number below such number), provided that this authority shall expire at the conclusion of the next annual general meeting of the Company after the passing of the resolution, save that the Company may make an offer or agreement before the expiry of this authority which would or might require relevant securities to be allotted after such expiry and the Directors may allot relevant securities pursuant to any such offer or agreement as if the authority conferred by this resolution had not expired.

## **Resolution 9: Disapplication of statutory pre-emption rights**

The Board is seeking disapplication of pre-emption rights for cash issues of up to a certain proportion of the Company's issued share capital. As consistent with previous years, the Board is seeking to renew the disapplication of pre-emption rights for cash issues of up to the number of Ordinary Shares of one penny each determined in accordance with Resolution 8 above.

Summit, in common with other similar sized biotechnology companies, has the potential for high growth. The Company focus is on progressing its clinical-stage drug programmes for the treatment of Duchenne muscular dystrophy ("DMD") and *C. difficile* infection ("CDI"), two diseases for which there are no existing or only inadequate therapies. As detailed in the 2016 Annual Report, the DMD and CDI programmes achieved important clinical milestones during the period under review. In order to be able to maintain the development of these programmes in a timely manner, the Company will in the future require additional funds. In light of Summit's size and status of being a pre-revenue generating company, the Board believes that equity financings are an appropriate method to support any potential future funding requirements.

Summit's Ordinary Shares trade on the AIM market of the London Stock Exchange and its American Depositary Shares ("ADSs") trade on the NASDAQ Global Market. In the event of an equity financing, having authorities for the disapplication of pre-emption rights should allow the Company to raise funds more efficiently in either, or both markets, on the best terms available and in a timely fashion and may help to avoid unnecessary dilution of existing shareholders.

Consequently, given the factors summarised above, the board believes the level of disapplication of pre-emption rights being sought at the AGM to be appropriate to enable completion of an equity offering of new Ordinary Shares and or ADSs at the appropriate time and under the appropriate conditions.

This authority will expire at the conclusion of the annual general meeting to be held in calendar year 2017.

Resolution 9 is proposed as a special resolution which mean that for the resolution to be passed, at least three-quarters of the votes cast must be cast in its favour. The remaining resolutions are proposed as ordinary resolutions which means that for each of those resolutions to be passed, more than half the votes cast must be cast in its favour.

### **3. Action to be taken**

Shareholders will find enclosed with this Document a Form of Proxy for use in connection with the Annual General Meeting. The Form of Proxy should be completed and returned in accordance with the instructions thereon so as to be received by Capita Asset Services, PXS, 34 Beckenham Road, Beckenham, BR3 4TU as soon as possible and in any event not later than 48 hours before the time of the AGM. Completion and return of the Form of Proxy will not prevent a Shareholder from attending and voting at the meeting should he/she so wish.

The proposals can only be implemented if the Resolutions are approved by the requisite majority at the Annual General Meeting. It is therefore important that you either vote in person or by proxy at the Annual General Meeting.

Shareholders are reminded that, if their Ordinary Shares are held in the name of a nominee, only that nominee or its duly appointed proxy can be counted in the quorum at the Annual General Meeting.

### **4. Recommendation**

The Board considers that the Resolutions to be proposed at the AGM are in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors unanimously recommend that you vote in favour of the Resolutions set out in the Notice of the Annual General Meeting as the Directors intend to do so in respect of their own beneficial shareholdings.

Whether or not you are able to attend the Annual General Meeting in person, please read the Notice of the Annual General Meeting set out at the end of this Document and the enclosed Form of Proxy, including the notes thereto, to ensure you are able to record your votes in respect of the Resolutions to be proposed at the Annual General Meeting.

Yours sincerely



**Frank Armstrong, FRCPE, FFPM**  
Non-Executive Chairman

# Notice of Annual General Meeting

## Summit Therapeutics PLC

Registered in England and Wales with number 05197494

NOTICE is hereby given that the 2016 Annual General Meeting of Summit Therapeutics PLC will be held at the Milton Park Innovation Centre, 99 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY at 10.30 a.m. on 18 July 2016 to consider and, if thought fit, pass Resolutions 1 to 8 as ordinary resolutions and Resolution 9 as a special resolution:

### **Resolution 1**

**THAT** the report of the Directors and the accounts for the year ended 31 January 2016, together with the report of the auditors and the strategic report be and are hereby received and adopted.

### **Resolution 2**

**THAT** PricewaterhouseCoopers LLP be and is hereby re-appointed as the Company's auditor until the conclusion of the next general meeting at which accounts are laid before the Company and that the Directors be and are hereby authorised to fix the remuneration of PricewaterhouseCoopers LLP as the auditor of the Company.

### **Resolution 3**

**THAT** the Directors' Remuneration Policy set out on pages 30 to 37 of the Annual Report, be approved and such Directors' Remuneration Policy to take effect from the date of its approval.

### **Resolution 4**

**THAT** the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy referred to in Resolution 3 above) contained on pages 38 to 44 of the Annual Report be approved.

### **Resolution 5**

**THAT** Professor Stephen Davies, who is retiring in accordance with article 89 of the Company's Articles, be and is hereby re-elected as a Director of the Company.

### **Resolution 6**

**THAT** Mr Leopoldo Zambetti, who is retiring in accordance with article 89 of the Company's Articles, be and is hereby re-elected as a Director of the Company.

### **Resolution 7**

**THAT** Dr Barry Price, who offers himself for re-election, be and is hereby re-elected as a Director of the Company.

### **Resolution 8**

**THAT** the Directors of the Company be and are hereby generally and unconditionally authorised, pursuant to section 551 of the Companies Act 2006 (the "Act"), in addition to any such authority previously granted and which has not expired, to issue and allot, or grant rights to subscribe for or convert any securities into, up to such number of Ordinary Shares of one penny each in the capital of the Company ("Ordinary Shares") as is equal to one third of the number of Ordinary Shares in issue at 5.00 p.m. BST on 17 July 2016 (or, if such number is not a whole number, then the nearest whole number below such number), provided that this authority shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution, save that the Company may make an offer or agreement before the expiry of this authority which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities pursuant to any such offer or agreement as if the authority conferred by this resolution had not expired.

### **Resolution 9**

**THAT**, subject to and conditional upon the passing of Resolution 8, the Directors of the Company be and are hereby generally empowered, pursuant to section 570 of the Act, in addition to any existing authorities under that section, to allot equity securities (as defined in section 560(1) of the Act) for cash pursuant to the authority conferred by Resolution 8 as if section 561 of the Act did not apply to such allotment, provided that this power shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution, save that the Company may make an offer or agreement before the expiry of this power which would or might require equity securities to be allotted for cash after such expiry and the Directors may allot equity securities for cash pursuant to any such offer or agreement as if the power conferred by this resolution had not expired.

By Order of the Board

**Melissa Strange**

Company Secretary

Dated 16 June 2016

# Explanatory Notes

## 1. Entitlement to attend and vote

Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, the Company specifies that only those members registered on the Company's register of members at:

- close of business on 15 July 2016; or,
- if this Annual General Meeting is adjourned, at close of business on the day two days prior to the adjourned meeting, shall be entitled to attend and vote at the meeting.

## 2. Appointment of proxies

If you are a member of the Company at the time set out in note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the Annual General Meeting and you should have received a proxy form with this notice of meeting. You can only appoint a proxy using the procedures set out in these notes and the notes to the proxy form.

A proxy does not need to be a member of the Company but must attend the meeting to represent you. Details of how to appoint the Chairman of the meeting or another person as your proxy using the proxy form are set out in the notes to the proxy form. If you wish your proxy to speak on your behalf at the meeting you will need to appoint your own choice of proxy (not the Chairman) and give your instructions directly to them.

You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, you may photocopy the proxy form provided and submit all such forms to Capita Asset Services.

To appoint one or more proxies or to give an instruction to a proxy (whether previously appointed or otherwise) via the CREST system, CREST messages must be received by the issuer's agent (ID number RA10) by 10.30 a.m. on 14 July 2016. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp generated by the CREST system) from which the issuer's agent is able to retrieve the message. The Company may treat as invalid a proxy appointment sent by CREST in the circumstances set out in regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

To direct your proxy how to vote on the resolutions, mark the appropriate box with an "X". A vote "withheld" is not a vote in law, which means that the vote will not be counted in the calculation of votes "For" or "Against" the resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting.

## 3. Appointment of proxy using hard copy proxy form

The notes to the proxy form explain how to direct your proxy how to vote on each resolution or withhold their vote.

To appoint a proxy using the proxy form, the form must be:

- completed and signed;
- sent or delivered to Capita Asset Services, PXS, 34 Beckenham Road, Beckenham, BR3 4TU; and
- received by Capita Asset Services no later than 10.30 a.m. on 14 July 2016.

In the case of a member which is a company, the proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any corporation which is a member may also appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member provided that they do not do so in relation to the same shares.

Any power of attorney or any other authority under which the proxy form is signed (or a duly certified copy of such power or authority) must be included with the proxy form.

## 4. Appointment of proxy by joint members

In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).

## 5. Changing proxy instructions

To change your proxy instructions simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also apply in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded.

Where you have appointed a proxy using the hard-copy proxy form and would like to change the instructions using another hard-copy proxy form, please contact Capita Asset Services.

If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence. If the Company is unable to determine which appointment was last validly received, none of them shall be treated as valid in respect of that share.

Any alterations made to the Proxy Form should be initialled.

# Explanatory Notes continued

## **6. Termination of proxy appointments**

In order to revoke a proxy instruction you will need to inform the Company by sending a signed hard copy notice clearly stating your intention to revoke your proxy appointment as above. In the case of a member which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice.

The revocation notice must be received by Capita Registrars no later than the commencement of the meeting or any adjourned meeting. If you attempt to revoke your proxy appointment but the revocation is received after the time specified then, subject to the paragraph directly below, your proxy appointment will remain valid.

Appointment of a proxy does not preclude you from attending the meeting and voting in person. If you have appointed a proxy and attend the meeting in person, your proxy appointment will automatically be terminated.

## **7. Website publication**

Shareholders should note that, on a request made by shareholders of the Company under Section 527 of the Companies Act 2006, the Company may be required to publish on a website a statement setting out any matter relating to (i) the audit of the Company's accounts (including the auditors' report and the conduct of the audit) that are to be laid before the AGM for the financial year ended 31 January 2016; or (ii) any circumstance connected with an auditor of the Company appointed for the financial year ended 31 January 2016 ceasing to hold office since the previous meeting at which annual accounts and reports were laid. The Company may not require the shareholders requesting any such website publication to pay its expenses in complying with Section 527 or 528 (requirements as to website availability) of the Companies Act 2006. Where the Company is required to place a statement on a website under section 527 of the Companies Act 2006, it must forward the statement to the Company's auditor not later than the time when it makes the statement available on the website. The business which may be dealt with at the AGM for the relevant financial year includes any statement that the Company has been required under Section 527 of the Companies Act 2006 to publish on a website.

## **8. Issued shares and total voting rights**

As at 6.00 p.m. on 15 June 2016, the Company's issued Ordinary Share capital comprised 61,467,785 Ordinary Shares of one penny each. Each Ordinary Share carries the right to one vote at the Annual General Meeting of the Company and, therefore, the total number of voting rights in the Company as at 6.00 p.m. on 15 June 2016 is 61,467,785.

## **9. Communication**

If you have any questions, please call Capita Asset Services on 0871 664 0300. Calls cost 12 pence per minute plus your Company's access charge. If you are outside the United Kingdom, please call +44 371 664 0300. Calls outside the United Kingdom will be charged at the applicable international rate. We are open between 9.00 a.m. to 5.30 p.m., Monday to Friday excluding public holidays in England and Wales.

You may not use any electronic address provided either in this Notice of Annual General Meeting or any related documents to communicate with the Company for any purposes other than those expressly stated.